27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
The following are key catalysts in the unfolding week that a biotech investor should stay tuned to.
Conferences
Barclays Global Healthcare Conference: March 10-12 in Miami, Florida.
American Academy of Allergy Asthma and Immunology, or AAAAI, Annual Meeting: March 13-16 in Philadelphia, Pennsylvania.
PDUFA Dates
The FDA is set to rule on Bristol-Myers Squibb Co's (NYSE:BMY) sBLA for Opdivo + Yervoy as a treatment option for patients with advanced hepatocellular carcinoma who were previously treated with Bayer AG (OTC:BAYRY) and Onyx Pharma's Nexavar. The PDUFA date has been set for Tuesday.
Clinical Readouts
Blueprint Medicines Corp (NASDAQ:BPMC) is scheduled to present at the AAAAI annual meeting with Phase 2 data for Avapritinib, which is being evaluated for treating indolent and smoldering systemic mastocytosis.
See also: Attention Biotech Investors: Mark Your Calendar For These March PDUFA Dates
Earnings
Want Private Access to Benzinga Analyst?
Check out the latest strategies our team of experts are using every week so that you can always adapt to the market like the pros!—Get FULL Access to This Week's Webinar Here.
Monday
- Matinas BioPharma Holdings Inc (NYSE:MTNB) (before the market open)
- Minerva Neurosciences Inc (NASDAQ:NERV) (before the market open)
- BioXcel Therapeutics Inc (NASDAQ:BTAI) (before the market open)
- Assertio Therapeutics Inc (NASDAQ:ASRT) (after the close)
- SI-Bone Inc (NASDAQ:SIBN) (after the close)
- Xenon Pharmaceuticals Inc (NASDAQ:XENE) (after the close)
- Organogenesis Holdings Inc (NASDAQ:ORGO) (after the close)
- Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) (after the close)
Tuesday
- Precision BioSciences Inc (NASDAQ:DTIL) (time not provided)
- Akebia Therapeutics Inc (NASDAQ:AKBA) (before the market open)
- Catabasis Pharmaceuticals Inc (NASDAQ:CATB) (before the market open)
- InspireMD Inc (NYSE:NSPR) (before the market open)
- ChemoCentryx Inc (NASDAQ:CCXI) (after the close)
- CV Sciences Inc (OTC:CVSI) (after the close)
- Fulgent Genetics Inc (NASDAQ:FLGT) (after the close)
- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) (after the close)
- RA Medical Systems Inc (NYSE:RMED) (after the close)
- Protagonist Therapeutics Inc (NASDAQ:PTGX) (after the close)
Wednesday
- Xeris Pharmaceuticals Inc (NASDAQ:XERS) (before the market open)
- Liquidia Technologies Inc (NASDAQ:LQDA) (before the market open)
- Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) (before the market open)
- INmune Bio Inc (NASDAQ:INMB) (before the market open)
- Clearside Biomedical Inc (NASDAQ:CLSD) (after the close)
- Calithera Biosciences Inc (NASDAQ:CALA) (after the close)
- Unity Biotechnology Inc (NASDAQ:UBX) (after the close)
- Navidea Biopharmaceuticals Inc (NYSE:NAVB) (after the close)
- Cumberland Pharmaceuticals, Inc. (NASDAQ:CPIX) (after the close)
- BioLife Solutions Inc (NASDAQ:BLFS) (after the close)
- Dynavax Technologies Corporation (NASDAQ:DVAX) (after the close)
- Miragen Therapeutics Inc (NASDAQ:MGEN) (after the close)
- Pfenex Inc (NYSE:PFNX) (after the close)
- Thursday
- Aquestive Therapeutics Inc (NASDAQ:AQST) (before the market open)
- Avadel Pharmaceuticals PLC (NASDAQ:AVDL) (before the market open)
- Axsome Therapeutics Inc (NASDAQ:AXSM) (before the market open)
- Aldeyra Therapeutics Inc (NASDAQ:ALDX) (before the market open)
- Selecta Biosciences Inc (NASDAQ:SELB) (before the market open)
- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) (before the market open)
- Provention Bio Inc (NASDAQ:PRVB) (before the market open)
- Protalix Biotherapeutics Inc (NYSE:PLX) (before the market open)
- Evofem Biosciences Inc (NASDAQ:EVFM) (before the market open)
- China Biologic Products Holdings Inc (NASDAQ:CBPO) (before the market open)
- Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) (before the market open)
- Pieris Pharmaceuticals Inc (NASDAQ:PIRS) (before the market open)
- X4 Pharmaceuticals Inc (NASDAQ:XFOR) (before the market open)
- Polarityte Inc (NASDAQ:PTE) (before the market open)
- Rubius Therapeutics Inc (NASDAQ:RUBY) (before the market open)
- Agenus Inc (NASDAQ:AGEN) (before the market open)
- ADMA Biologics Inc (NASDAQ:ADMA) (after the close)
- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) (after the close)
- Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) (after the close)
- Celcuity Inc (NASDAQ:CELC) (after the close)
- Lineage Cell Therapeutics Inc (NYSE:LCTX) (after the close)
- Chembio Diagnostics Inc (NASDAQ:CEMI) (after the close)
- Harpoon Therapeutics Inc (NASDAQ:HARP) (after the close)
- Flexion Therapeutics Inc (NASDAQ:FLXN) (after the close)
- Neoleukin Therapeutics Inc (NASDAQ:NLTX) (after the close)
- Rockwell Medical Inc (NASDAQ:RMTI) (after the close)
- Inovio Pharmaceuticals Inc (NASDAQ:INO) (after the close)
- Savara Inc (NASDAQ:SVRA) (after the close)
- Ocular Therapeutix Inc (NASDAQ:OCUL) (after the close)
- Y-mAbs Therapeutics, Inc (NASDAQ:YMAB) (after the close)
Friday
- PLx Pharma Inc (NASDAQ:PLXP) (before the market open)
- Achieve Life Sciences Inc (NASDAQ:ACHV) (before the market open)
IPOs
Imara, a biopharma company that is developing therapies for rare hemoglobinopathies, has filed to offer 4.45 million shares in an IPO, to be priced between $16 and $18. The company seeks to list its shares on the Nasdaq under the ticker symbol "IMRA."
IPO Quiet Period Expiry
Revolution Medicines Inc (NASDAQ:RVMD)
Related Link: How The COVID-19 Outbreak Is Benefiting Biotech Investors
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.